Keyphrases
Moderate to Severe
100%
Placebo
100%
Tolerability
100%
Severe COPD
100%
COPD Patients
100%
CCR1 Antagonist
100%
Plasma Concentration
40%
Twice Daily
40%
Treatment-related
40%
Lung Function
40%
Treatment Effect
20%
Placebo-controlled Study
20%
Deep Vein Thrombosis
20%
Treatment Group
20%
Clinical Efficacy
20%
Treatment-related Adverse Events
20%
Change from Baseline
20%
Serious Adverse Events
20%
Forced Expiratory Volume in 1 Second (FEV1)
20%
First Dose
20%
Functional Capacity
20%
Dyspnea Score
20%
Turbuhaler
20%
BODE Index
20%
Functional Health
20%
6-minute Walk Test (6MWT)
20%
Therapeutic Area
20%
Health Status Measures
20%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Tolerability
100%
Chronic Obstructive Lung Disease
100%
Chemokine Receptor CCR1 Antagonist
100%
Adverse Event
40%
Placebo-Controlled Study
20%
Deep Vein Thrombosis
20%
Functional Status
20%
Health Status
20%
Dyspnea
20%
Metered-Dose Inhaler
20%